Disturbing the histone code in leukemia: Translocations and mutations affecting histone methyl transferases

Cancer Genetics

Volumn 208, Issue 5, 2015, Pages 192-205

  Chopra, Martin ^a   Bohlander, Stefan K ^a  

^a THE UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Cancer; Epigenetics; Histone methylation; Histone methyltransferases; Leukemia

Indexed keywords

1 [3 [[5 (4 AMINO 5 BROMO 7H PYRROLO[2,3 D]PYRIMIDIN 7 YL) 3,4 DIHYDROXYTETRAHYDRO 2 FURFURYL](ISOPROPYL)AMINO]PROPYL] 3 (4 TERT BUTYLPHENYL)UREA; 3 DEAZANEPLANOCIN A; ANTILEUKEMIC AGENT; EI 1; EPZ 004777; EPZ 005687; GSK 126; GSK 2816126; GSK 343; GSK 926; HISTONE DEMETHYLASE; HISTONE METHYLTRANSFERASE; LYSINE; MIXED LINEAGE LEUKEMIA PROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN 1; MM 102; MM 401; PINOMETOSTAT; PROTEIN DOT1L; PROTEIN SETD2; TAZEMETOSTAT; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; DOT1L PROTEIN, HUMAN; ENZYME INHIBITOR; EZH2 PROTEIN, HUMAN; HISTONE; HISTONE LYSINE METHYLTRANSFERASE; METHYLTRANSFERASE; MLL PROTEIN, HUMAN; POLYCOMB REPRESSIVE COMPLEX 2; SET2 PROTEIN, HUMAN;

AMINO TERMINAL SEQUENCE; APOPTOSIS; BASE PAIRING; BINDING SITE; CANCER GENETICS; CARBOXY TERMINAL SEQUENCE; CELL CYCLE ARREST; CHROMOSOME TRANSLOCATION; COPY NUMBER VARIATION; DRUG POTENCY; DRUG SYNTHESIS; EPIGENETICS; FOLLICULAR LYMPHOMA; GAIN OF FUNCTION MUTATION; GENE DUPLICATION; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; GENE REPRESSION; GENE SILENCING; GENE STRUCTURE; GENETIC TRANSCRIPTION; HISTONE METHYLATION; HUMAN; LARGE CELL LYMPHOMA; LEUKEMIA; LEUKEMOGENESIS; MALIGNANT TRANSFORMATION; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; NUCLEOSOME; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MOTIF; PROTEIN PROCESSING; PROTEIN TARGETING; REVIEW; SOMATIC MUTATION; TRANSCRIPTION INITIATION; ANTAGONISTS AND INHIBITORS; CELL TRANSFORMATION; CHEMISTRY; GENE TRANSLOCATION; GENETICS;

CELL TRANSFORMATION, NEOPLASTIC; ENZYME INHIBITORS; HISTONE-LYSINE N-METHYLTRANSFERASE; HISTONES; HUMANS; LEUKEMIA; LYSINE; METHYLTRANSFERASES; MYELOID-LYMPHOID LEUKEMIA PROTEIN; POLYCOMB REPRESSIVE COMPLEX 2; TRANSLOCATION, GENETIC;

EID: 84930577272     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2014.10.005     Document Type: Review

References (203)

1. Grigoropoulos N.F., Petter R., Van 't Veer M.B., et al. Leukaemia update. Part 1: diagnosis and management. BMJ 2013, 346:f1660.
2. Jabbour E., Kantarjian H. Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management. Am J Hematol 2014, 89:547-556.
3. Cancer Genome Atlas Research Network Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. NEngl J Med 2013, 368:2059-2074.
4. O'Carroll D., Erhardt S., Pagani M., et al. The polycomb-group gene Ezh2 is required for early mouse development. Mol Cell Biol 2001, 21:4330-4336.
5. Strahl B.D., Allis C.D. The language of covalent histone modifications. Nature 2000, 403:41-45.
6. Jenuwein T., Allis C.D. Translating the histone code. Science 2001, 293:1074-1080.
7. Musselman C.A., Kutateladze T.G. Handpicking epigenetic marks with PHD fingers. Nucleic Acids Res 2011, 39:9061-9071.
8. Justin N., De Marco V., Aasland R., et al. Reading, writing and editing methylated lysines on histone tails: new insights from recent structural studies. Curr Opin Struct Biol 2010, 20:730-738.
9. Taverna S.D., Li H., Ruthenburg A.J., et al. How chromatin-binding modules interpret histone modifications: lessons from professional pocket pickers. Nat Struct Mol Biol 2007, 14:1025-1040.
10. Arrowsmith C.H., Bountra C., Fish P.V., et al. Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov 2012, 11:384-400.
11. Ernst J., Kheradpour P., Mikkelsen T.S., et al. Mapping and analysis of chromatin state dynamics in nine human cell types. Nature 2011, 473:43-49.
12. Clarke S. Protein methylation. Curr Opin Cell Biol 1993, 5:977-983.
13. Murray K. The occurrence of epsilon-N-methyl lysine in histones. Biochemistry 1964, 3:10-15.
14. Richon V.M., Johnston D., Sneeringer C.J., et al. Chemogenetic analysis of human protein methyltransferases. Chem Biol Drug Des 2011, 78:199-210.
15. Martin C., Zhang Y. The diverse functions of histone lysine methylation. Nat Rev Mol Cell Biol 2005, 6:838-849.
16. Greer E.L., Shi Y. Histone methylation: a dynamic mark in health, disease and inheritance. Nat Rev Genet 2012, 13:343-357.
17. Rhie S.K., Hazelett D.J., Coetzee S.G., et al. Nucleosome positioning and histone modifications define relationships between regulatory elements and nearby gene expression in breast epithelial cells. BMC Genomics 2014, 15:331.
18. Arnold C.D., Gerlach D., Stelzer C., et al. Genome-wide quantitative enhancer activity maps identified by STARR-seq. Science 2013, 339:1074-1077.
19. Minard M.E., Jain A.K., Barton M.C. Analysis of epigenetic alterations to chromatin during development. Genesis 2009, 47:559-572.
20. Cavalli G. Chromatin and epigenetics in development: blending cellular memory with cell fate plasticity. Development 2006, 133:2089-2094.
21. Cosgrove M.S., Patel A. Mixed lineage leukemia: a structure-function perspective of the MLL1 protein. FEBS J 2010, 277:1832-1842.
22. Djabali M., Selleri L., Parry P., et al. Atrithorax-like gene is interrupted by chromosome 11q23 translocations in acute leukaemias. Nat Genet 1992, 2:113-118.
23. Argiropoulos B., Humphries R.K. Hox genes in hematopoiesis and leukemogenesis. Oncogene 2007, 26:6766-6776.
24. Ringrose L., Paro R. Epigenetic regulation of cellular memory by the Polycomb and Trithorax group proteins. Annu Rev Genet 2004, 38:413-443.
25. Pearson J.C., Lemons D., McGinnis W. Modulating Hox gene functions during animal body patterning. Nat Rev Genet 2005, 6:893-904.
26. Alharbi R.A., Pettengell R., Pandha H.S., et al. The role of HOX genes in normal hematopoiesis and acute leukemia. Leukemia 2013, 27:1000-1008.
27. Yagi H., Deguchi K., Aono A., et al. Growth disturbance in fetal liver hematopoiesis of Mll-mutant mice. Blood 1998, 92:108-117.
28. Hess J.L., Yu B.D., Li B., et al. Defects in yolk sac hematopoiesis in Mll-null embryos. Blood 1997, 90:1799-1806.
29. Huang Y., Sitwala K., Bronstein J., et al. Identification and characterization of Hoxa9 binding sites in hematopoietic cells. Blood 2012, 119:388-398.
30. Faber J., Krivtsov A.V., Stubbs M.C., et al. HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood 2009, 113:2375-2385.
31. Wang P., Lin C., Smith E.R., et al. Global analysis of H3K4 methylation defines MLL family member targets and points to a role for MLL1-mediated H3K4 methylation in the regulation of transcriptional initiation by RNA polymerase II. Mol Cell Biol 2009, 29:6074-6085.
32. Milne T.A., Briggs S.D., Brock H.W., et al. MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol Cell 2002, 10:1107-1117.
33. Lauberth S.M., Nakayama T., Wu X., et al. H3K4me3 interactions with TAF3 regulate preinitiation complex assembly and selective gene activation. Cell 2013, 152:1021-1036.
34. Chang P.Y., Hom R.A., Musselman C.A., et al. Binding of the MLL PHD3 finger to histone H3K4me3 is required for MLL-dependent gene transcription. JMol Biol 2010, 400:137-144.
35. Guenther M.G., Jenner R.G., Chevalier B., et al. Global and Hox-specific roles for the MLL1 methyltransferase. Proc Natl Acad Sci U S A 2005, 102:8603-8608.
36. Allen M.D., Grummitt C.G., Hilcenko C., et al. Solution structure of the nonmethyl-CpG-binding CXXC domain of the leukaemia-associated MLL histone methyltransferase. EMBO J 2006, 25:4503-4512.
37. Birke M., Schreiner S., García-Cuéllar M.P., et al. The MT domain of the proto-oncoprotein MLL binds to CpG-containing DNA and discriminates against methylation. Nucleic Acids Res 2002, 30:958-965.
38. Zeleznik-Le N.J., Harden A.M., Rowley J.D. 11q23 translocations split the "AT-hook" cruciform DNA-binding region and the transcriptional repression domain from the activation domain of the mixed-lineage leukemia (MLL) gene. Proc Natl Acad Sci US A 1994, 91:10610-10614.
39. Nakamura T., Mori T., Tada S., et al. ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation. Mol Cell 2002, 10:1119-1128.
40. Dou Y., Milne T.A., Ruthenburg A.J., et al. Regulation of MLL1 H3K4 methyltransferase activity by its core components. Nat Struct Mol Biol 2006, 13:713-719.
41. Hughes C.M., Rozenblatt-Rosen O., Milne T.A., et al. Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus. Mol Cell 2004, 13:587-597.
42. Yokoyama A., Wang Z., Wysocka J., et al. Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression. Mol Cell Biol 2004, 24:5639-5649.
43. De Braekeleer M., Morel F., Le Bris M.J., et al. The MLL gene and translocations involving chromosomal band 11q23 in acute leukemia. Anticancer Res 2005, 25:1931-1944.
44. Felix C.A. Secondary leukemias induced by topoisomerase-targeted drugs. Biochim Biophys Acta 1998, 1400:233-255.
45. Baffa R., Negrini M., Schichman S.A., et al. Involvement of the ALL-1 gene in a solid tumor. Proc Natl Acad Sci U S A 1995, 92:4922-4926.
46. Meyer C., Hofmann J., Burmeister T., et al. The MLL recombinome of acute leukemias in 2013. Leukemia 2013, 27:2165-2176.
47. Muntean A.G., Hess J.L. The pathogenesis of mixed lineage leukemia. Annu Rev Pathol 2012, 7:283-301.
48. Meyer C., Kowarz E., Hofmann J., et al. New insights to the MLLrecombinome of acute leukemias. Leukemia 2009, 23:1490-1499.
49. Hess J.L. MLL: a histone methyltransferase disrupted in leukemia. Trends Mol Med 2004, 10:500-507.
50. Muntean A.G., Giannola D., Udager A.M., et al. The PHD fingers of MLL block MLL fusion protein-mediated transformation. Blood 2008, 112:4690-4693.
51. Thiel A.T., Blessington P., Zou T., et al. MLL-AF9-induced leukemogenesis requires coexpression of the wild-type Mll allele. Cancer Cell 2010, 17:148-159.
52. Mishra B.P., Zaffuto K.M., Artinger E.L., et al. The histone methyltransferase activity of MLL1 is dispensable for hematopoiesis and leukemogenesis. Cell Rep 2014, 7:1239-1247.
53. Bursen A., Schwabe K., Rüster B., et al. The AF4. MLL fusion protein is capable of inducing ALL in mice without requirement of MLL. AF4. Blood 2010, 115:3570-3579.
54. Kohlmann A., Schoch C., Dugas M., et al. New insights into MLL gene rearranged acute leukemias using gene expression profiling: shared pathways, lineage commitment, and partner genes. Leukemia 2005, 19:953-964.
55. Ferrando A.A., Armstrong S.A., Neuberg D.S., et al. Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. Blood 2003, 102:262-268.
56. Rozovskaia T., Feinstein E., Mor O., et al. Upregulation of Meis1 and HoxA9 in acute lymphocytic leukemias with the t (4: 11) abnormality. Oncogene 2001, 20:874-878.
57. Wong P., Iwasaki M., Somervaille T.C., et al. Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential. Genes Dev 2007, 21:2762-2774.
58. Ayton P.M., Cleary M.L. Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev 2003, 17:2298-2307.
59. So C.W., Karsunky H., Wong P., et al. Leukemic transformation of hematopoietic progenitors by MLL-GAS7 in the absence of Hoxa7 or Hoxa9. Blood 2004, 103:3192-3199.
60. Zeisig B.B., Milne T., García-Cuéllar M.P., et al. Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization. Mol Cell Biol 2004, 24:617-628.
61. Park G., Gong Z., Chen J., et al. Characterization of the DOT1L network: implications of diverse roles for DOT1L. Protein J 2010, 29:213-223.
62. Zeisig D.T., Bittner C.B., Zeisig B.B., et al. The eleven-nineteen-leukemia protein ENL connects nuclear MLL fusion partners with chromatin. Oncogene 2005, 24:5525-5532.
63. Monroe S.C., Jo S.Y., Sanders D.S., et al. MLL-AF9 and MLL-ENL alter the dynamic association of transcriptional regulators withgenes critical for leukemia. Exp Hematol 2011, 39:77-86.e1-e5.
64. Yokoyama A., Lin M., Naresh A., et al. Ahigher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription. Cancer Cell 2010, 17:198-212.
65. Lin C., Smith E.R., Takahashi H., et al. AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. Mol Cell 2010, 37:429-437.
66. Mueller D., Bach C., Zeisig D., et al. Arole for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. Blood 2007, 110:4445-4454.
67. Bitoun E., Oliver P.L., Davies K.E. The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling. Hum Mol Genet 2007, 16:92-106.
68. Kwak H., Lis J.T. Control of transcriptional elongation. Annu Rev Genet 2013, 47:483-508.
69. Mueller D., García-Cuéllar M.P., Bach C., et al. Misguided transcriptional elongation causes mixed lineage leukemia. PLoS Biol 2009, 7:e1000249.
70. Okada Y., Feng Q., Lin Y., et al. hDOT1L links histone methylation to leukemogenesis. Cell 2005, 121:167-178.
71. Jo S.Y., Granowicz E.M., Maillard I., et al. Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation. Blood 2011, 117:4759-4768.
72. Chang M.J., Wu H., Achille N.J., et al. Histone H3 lysine 79 methyltransferase Dot1 is required for immortalization by MLL oncogenes. Cancer Res 2010, 70:10234-10242.
73. Deshpande A.J., Chen L., Fazio M., et al. Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l. Blood 2013, 121:2533-2541.
74. Krivtsov A.V., Feng Z., Lemieux M.E., et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell 2008, 14:355-368.
75. Lavau C., Du C., Thirman M., et al. Chromatin-related properties of CBP fused to MLL generate a myelodysplastic-like syndrome that evolves into myeloid leukemia. EMBO J 2000, 19:4655-4664.
76. Sobulo O.M., Borrow J., Tomek R., et al. MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3). Proc Natl Acad Sci U S A 1997, 94:8732-8737.
77. Ernst P., Wang J., Huang M., et al. MLL and CREB bind cooperatively to the nuclear coactivator CREB-binding protein. Mol Cell Biol 2001, 21:2249-2258.
78. Cheung N., Chan L.C., Thompson A., et al. Protein arginine-methyltransferase-dependent oncogenesis. Nat Cell Biol 2007, 9:1208-1215.
79. Eguchi M., Eguchi-Ishimae M., Greaves M. The small oligomerization domain of gephyrin converts MLL to an oncogene. Blood 2004, 103:3876-3882.
80. So C.W., Lin M., Ayton P.M., et al. Dimerization contributes to oncogenic activation of MLL chimeras in acute leukemias. Cancer Cell 2003, 4:99-110.
81. Martin M.E., Milne T.A., Bloyer S., et al. Dimerization of MLL fusion proteins immortalizes hematopoietic cells. Cancer Cell 2003, 4:197-207.
82. Dobson C.L., Warren A.J., Pannell R., et al. Tumorigenesis in mice with a fusion of the leukaemia oncogene Mll and the bacterial lacZ gene. EMBO J 2000, 19:843-851.
83. Poppe B., Vandesompele J., Schoch C., et al. Expression analyses identify MLL as a prominent target of 11q23 amplification and support an etiologic role for MLL gain of function in myeloid malignancies. Blood 2004, 103:229-235.
84. Avet-Loiseau H., Godon C., Li J.Y., et al. Amplification of the 11q23 region in acute myeloid leukemia. Genes Chromosomes Cancer 1999, 26:166-170.
85. Yu M., Honoki K., Andersen J., et al. MLL tandem duplication and multiple splicing in adult acute myeloid leukemia with normal karyotype. Leukemia 1996, 10:774-780.
86. Schichman S.A., Caligiuri M.A., Gu Y., et al. ALL-1 partial duplication in acute leukemia. Proc Natl Acad Sci U S A 1994, 91:6236-6239.
87. Whitman S.P., Liu S., Vukosavljevic T., et al. The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy. Blood 2005, 106:345-352.
88. Dorrance A.M., Liu S., Yuan W., et al. Mll partial tandem duplication induces aberrant Hox expression invivo via specific epigenetic alterations. JClin Invest 2006, 116:2707-2716.
89. Jones W.D., Dafou D., McEntagart M., et al. De novo mutations in MLL cause Wiedemann-Steiner syndrome. Am J Hum Genet 2012, 91:358-364.
90. Min J., Feng Q., Li Z., et al. Structure of the catalytic domain of human DOT1L, a non-SET domain nucleosomal histone methyltransferase. Cell 2003, 112:711-723.
91. Feng Q., Wang H., Ng H.H., et al. Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain. Curr Biol 2002, 12:1052-1058.
92. Wang Z., Zang C., Rosenfeld J.A., et al. Combinatorial patterns of histone acetylations and methylations in the human genome. Nat Genet 2008, 40:897-903.
93. Steger D.J., Lefterova M.I., Ying L., et al. DOT1L/KMT4 recruitment and H3K79 methylation are ubiquitously coupled with gene transcription in mammalian cells. Mol Cell Biol 2008, 28:2825-2839.
94. Vakoc C.R., Sachdeva M.M., Wang H., et al. Profile of histone lysine methylation across transcribed mammalian chromatin. Mol Cell Biol 2006, 26:9185-9195.
95. Krogan N.J., Dover J., Wood A., et al. The Paf1 complex is required for histone H3 methylation by COMPASS and Dot1p: linking transcriptional elongation to histone methylation. Mol Cell 2003, 11:721-729.
96. Jones B., Su H., Bhat A., et al. The histone H3K79 methyltransferase Dot1L is essential for mammalian development and heterochromatin structure. PLoS Genet 2008, 4:e1000190.
97. Barry E.R., Krueger W., Jakuba C.M., et al. ES cell cycle progression and differentiation require the action of the histone methyltransferase Dot1L. Stem Cells 2009, 27:1538-1547.
98. Wysocki R., Javaheri A., Allard S., et al. Role of Dot1-dependent histone H3 methylation in G1 and S phase DNA damage checkpoint functions of Rad9. Mol Cell Biol 2005, 25:8430-8443.
99. Giannattasio M., Lazzaro F., Plevani P., et al. The DNA damage checkpoint response requires histone H2B ubiquitination by Rad6-Bre1 and H3 methylation by Dot1. JBiol Chem 2005, 280:9879-9886.
100. Bernt K.M., Zhu N., Sinha A.U., et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 2011, 20:66-78.
101. Dreyling M.H., Martinez-Climent J.A., Zheng M., et al. The t (10;11)(p13;q14) in the U937 cell line results in the fusion of the AF10 gene and CALM, encoding a new member of the AP-3 clathrin assembly protein family. Proc Natl Acad Sci U S A 1996, 93:4804-4809.
102. Dreyling M.H., Schrader K., Fonatsch C., et al. MLL and CALM are fused to AF10 in morphologically distinct subsets of acute leukemia with translocation t(10;11): both rearrangements are associated with a poor prognosis. Blood 1998, 91:4662-4667.
103. Caudell D., Zhang Z., Chung Y.J., et al. Expression of a CALM-AF10 fusion gene leads to Hoxa cluster overexpression and acute leukemia in transgenic mice. Cancer Res 2007, 67:8022-8031.
104. Okada Y., Jiang Q., Lemieux M., et al. Leukaemic transformation by CALM-AF10 involves upregulation of Hoxa5 by hDOT1L. Nat Cell Biol 2006, 8:1017-1024.
105. Lin Y.H., Kakadia P.M., Chen Y., et al. Global reduction of the epigenetic H3K79 methylation mark and increased chromosomal instability in CALM-AF10-positive leukemias. Blood 2009, 114:651-658.
106. Van Vlierberghe P., van Grotel M., Tchinda J., et al. The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia. Blood 2008, 111:4668-4680.
107. Laible G., Wolf A., Dorn R., et al. Mammalian homologues of the Polycomb-group gene Enhancer of zeste mediate gene silencing in Drosophila heterochromatin and at S. cerevisiae telomeres. EMBO J 1997, 16:3219-3232.
108. Viré E., Brenner C., Deplus R., et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 2006, 439:871-874.
109. Cao R., Wang L., Wang H., et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 2002, 298:1039-1043.
110. Ezhkova E., Pasolli H.A., Parker J.S., et al. Ezh2 orchestrates gene expression for the stepwise differentiation of tissue-specific stem cells. Cell 2009, 136:1122-1135.
111. Kamminga L.M., Bystrykh L.V., de Boer A., et al. The Polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion. Blood 2006, 107:2170-2179.
112. Thiel A.T., Feng Z., Pant D.K., et al. The trithorax protein partner menin acts in tandem with EZH2 to suppress C/EBPα and differentiation in MLL-AF9 leukemia. Haematologica 2013, 98:918-927.
113. van Vlerken L.E., Kiefer C.M., Morehouse C., et al. EZH2 is required for breast and pancreatic cancer stem cell maintenance and can be used as a functional cancer stem cell reporter. Stem Cells Transl Med 2013, 2:43-52.
114. Sasaki D., Imaizumi Y., Hasegawa H., et al. Overexpression of Enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy. Haematologica 2011, 96:712-719.
115. Wagener N., Holland D., Bulkescher J., et al. The enhancer of zeste homolog 2 gene contributes to cell proliferation and apoptosis resistance in renal cell carcinoma cells. Int J Cancer 2008, 123:1545-1550.
116. Bachmann I.M., Halvorsen O.J., Collett K., et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. JClin Oncol 2006, 24:268-273.
117. Kleer C.G., Cao Q., Varambally S., et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A 2003, 100:11606-11611.
118. Varambally S., Dhanasekaran S.M., Zhou M., et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002, 419:624-629.
119. Morin R.D., Johnson N.A., Severson T.M., et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010, 42:181-185.
120. Sahasrabuddhe A.A., Chen X., Chung F., et al. Oncogenic Y641 mutations in EZH2 prevent Jak2/β-TrCP-mediated degradation. Oncogene 2014, [Epub ahead of print].
121. Yap D.B., Chu J., Berg T., et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 2011, 117:2451-2459.
122. Sneeringer C.J., Scott M.P., Kuntz K.W., et al. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc Natl Acad Sci U S A 2010, 107:20980-20985.
123. Guo S., Chan J.K., Iqbal J., et al. EZH2 mutations in follicular lymphoma from different ethnic groups and associated gene expression alterations. Clin Cancer Res 2014, 20:3078-3086.
124. Béguelin W., Popovic R., Teater M., et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 2013, 23:677-692.
125. Velichutina I., Shaknovich R., Geng H., et al. EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood 2010, 116:5247-5255.
126. Xu F., Li X., Wu L., et al. Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring. Ann Hematol 2011, 90:643-653.
127. Grubach L., Juhl-Christensen C., Rethmeier A., et al. Gene expression profiling of Polycomb, Hox and Meis genes in patients with acute myeloid leukaemia. Eur J Haematol 2008, 81:112-122.
128. Herrera-Merchan A., Arranz L., Ligos J.M., et al. Ectopic expression of the histone methyltransferase Ezh2 in haematopoietic stem cells causes myeloproliferative disease. Nat Commun 2012, 3:623.
129. Tanaka S., Miyagi S., Sashida G., et al. Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia. Blood 2012, 120:1107-1117.
130. Khan S.N., Jankowska A.M., Mahfouz R., et al. Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies. Leukemia 2013, 27:1301-1309.
131. Ernst T., Chase A.J., Score J., et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010, 42:722-726.
132. Makishima H., Jankowska A.M., Tiu R.V., et al. Novel homo-and hemizygous mutations in EZH2 in myeloid malignancies. Leukemia 2010, 24:1799-1804.
133. Nikoloski G., Langemeijer S.M.C., Kuiper R.P., et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 2010, 42:665-667.
134. Ntziachristos P., Tsirigos A., Van Vlierberghe P., et al. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat Med 2012, 18:298-301.
135. Grossmann V., Kohlmann A., Eder C., et al. Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance. Leukemia 2011, 25:877-879.
136. Guglielmelli P., Biamonte F., Score J., et al. EZH2 mutational status predicts poor survival in myelofibrosis. Blood 2011, 118:5227-5234.
137. Boultwood J., Perry J., Pellagatti A., et al. Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. Leukemia 2010, 24:1062-1065.
138. Rocquain J., Carbuccia N., Trouplin V., et al. Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. BMC Cancer 2010, 10:401.
139. Gelsi-Boyer V., Trouplin V., Adélaïde J., et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 2009, 145:788-800.
140. Ueda T., Sanada M., Matsui H., et al. EED mutants impair polycomb repressive complex 2 in myelodysplastic syndrome and related neoplasms. Leukemia 2012, 26:2557-2560.
141. Score J., Hidalgo-Curtis C., Jones A.V., et al. Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms. Blood 2012, 119:1208-1213.
142. Inoue D., Kitaura J., Togami K., et al. Myelodysplastic syndromes are induced by histone methylation-altering ASXL1 mutations. JClin Invest 2013, 123:4627-4640.
143. Abdel-Wahab O., Adli M., LaFave L.M., et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell 2012, 22:180-193.
144. Margueron R., Justin N., Ohno K., et al. Role of the polycomb protein EED in the propagation of repressive histone marks. Nature 2009, 461:762-767.
145. Thol F., Friesen I., Damm F., et al. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. JClin Oncol 2011, 29:2499-2506.
146. Gelsi-Boyer V., Trouplin V., Roquain J., et al. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. Br J Haematol 2010, 151:365-375.
147. Sun X.J., Wei J., Wu X.Y., et al. Identification and characterization of a novel human histone H3 lysine 36-specific methyltransferase. JBiol Chem 2005, 280:35261-35271.
148. Edmunds J.W., Mahadevan L.C., Clayton A.L. Dynamic histone H3 methylation during gene induction: HYPB/Setd2 mediates all H3K36 trimethylation. EMBO J 2008, 27:406-420.
149. Zhu X., He F., Zeng H., et al. Identification of functional cooperative mutations of SETD2 in human acute leukemia. Nat Genet 2014, 46:287-293.
150. Mar B.G., Bullinger L.B., McLean K.M., et al. Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia. Nat Commun 2014, 5:3469.
151. Nimura K., Ura K., Shiratori H., et al. Ahistone H3 lysine 36 trimethyltransferase links Nkx2-5 to Wolf-Hirschhorn syndrome. Nature 2009, 460:287-291.
152. Qiao Q., Li Y., Chen Z., et al. The structure of NSD1 reveals an autoregulatory mechanism underlying histone H3K36 methylation. JBiol Chem 2011, 286:8361-8368.
153. Shiba N., Ichikawa H., Taki T., et al. NUP98-NSD1 gene fusion and its related gene expression signature are strongly associated with a poor prognosis in pediatric acute myeloid leukemia. Genes Chromosomes Cancer 2013, 52:683-693.
154. Hollink I.H., van den Heuvel-Eibrink M.M., Arentsen-Peters S.T., et al. NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. Blood 2011, 118:3645-3656.
155. Jaju R.J., Fidler C., Haas O.A., et al. Anovel gene, NSD1, is fused to NUP98 in the t (5;11)(q35;p15.5) in de novo childhood acute myeloid leukemia. Blood 2001, 98:1264-1267.
156. Wang G.G., Cai L., Pasillas M.P., et al. NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis. Nat Cell Biol 2007, 9:804-812.
157. Rosati R., La Starza R., Veronese A., et al. NUP98 is fused to the NSD3 gene in acute myeloid leukemia associated with t(8;11)(p11.2;p15). Blood 2002, 99:3857-3860.
158. Tsukada Y., Fang J., Erdjument-Bromage H., et al. Histone demethylation by a family of JmjC domain-containing proteins. Nature 2006, 439:811-816.
159. Shi Y., Lan F., Matson C., et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 2004, 119:941-953.
160. Karytinos A., Forneris F., Profumo A., et al. Anovel mammalian flavin-dependent histone demethylase. JBiol Chem 2009, 284:17775-17782.
161. Thinnes C.C., England K.S., Kawamura A., et al. Targeting histone lysine demethylases - Progress, challenges, and the future. Biochim Biophys Acta 2014, [Epub ahead of print].
162. Højfeldt J.W., Agger K., Helin K. Histone lysine demethylases as targets for anticancer therapy. Nat Rev Drug Discov 2013, 12:917-930.
163. Nakamura S., Tan L., Nagata Y., et al. JmjC-domain containing histone demethylase 1B-mediated p15(Ink4b) suppression promotes the proliferation of leukemic progenitor cells through modulation of cell cycle progression in acute myeloid leukemia. Mol Carcinog 2013, 52:57-69.
164. Kim J.Y., Kim K.B., Eom G.H., et al. KDM3B is the H3K9 demethylase involved in transcriptional activation of lmo2 in leukemia. Mol Cell Biol 2012, 32:2917-2933.
165. He J., Nguyen A.T., Zhang Y. KDM2b/JHDM1b, an H3K36me2-specific demethylase, is required for initiation and maintenance of acute myeloid leukemia. Blood 2011, 117:3869-3880.
166. Sroczynska P., Cruickshank V.A., Bukowski J.P., et al. shRNA screening identifies JMJD1C as being required for leukemia maintenance. Blood 2014, 123:1870-1882.
167. Harris W.J., Huang X., Lynch J.T., et al. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell 2012, 21:473-487.
168. Mar B.G., Bullinger L., Basu E., et al. Sequencing histone-modifying enzymes identifies UTX mutations in acute lymphoblastic leukemia. Leukemia 2012, 26:1881-1883.
169. Jankowska A.M., Makishima H., Tiu R.V., et al. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood 2011, 118:3932-3941.
170. Chi P., Allis C.D., Wang G.G. Covalent histone modifications-miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer 2010, 10:457-469.
171. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 2007, 8:286-298.
172. Cao R., Zhang Y. The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr Opin Genet Dev 2004, 14:155-164.
173. Copeland R.A., Moyer M.P., Richon V.M. Targeting genetic alterations in protein methyltransferases for personalized cancer therapeutics. Oncogene 2013, 32:939-946.
174. Chiang P.K. Biological effects of inhibitors of S-adenosylhomocysteine hydrolase. Pharmacol Ther 1998, 77:115-134.
175. Cao F., Townsend E.C., Karatas H., et al. Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia. Mol Cell 2014, 53:247-261.
176. Karatas H., Townsend E.C., Bernard D., et al. Analysis of the binding of mixed lineage leukemia 1 (MLL1) and histone 3 peptides to WD repeat domain 5 (WDR5) for the design of inhibitors of the MLL1-WDR5 interaction. JMed Chem 2010, 53:5179-5185.
177. Karatas H., Townsend E.C., Cao F., et al. High-affinity, small-molecule peptidomimetic inhibitors of MLL1/WDR5 protein-protein interaction. JAm Chem Soc 2013, 135:669-682.
178. Senisterra G., Wu H., Allali-Hassani A., et al. Small-molecule inhibition of MLL activity by disruption of its interaction with WDR5. Biochem J 2013, 449:151-159.
179. Avdic V., Zhang P., Lanouette S., et al. Fine-tuning the stimulation of MLL1 methyltransferase activity by a histone H3-based peptide mimetic. FASEB J 2011, 25:960-967.
180. He S., Senter T.J., Pollock J., et al. High-affinity small-molecule inhibitors of the menin-mixed lineage leukemia (MLL) interaction closely mimic a natural protein-protein interaction. JMed Chem 2014, 57:1543-1556.
181. Shi A., Murai M.J., He S., et al. Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia. Blood 2012, 120:4461-4469.
182. Grembecka J., He S., Shi A., et al. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat Chem Biol 2012, 8:277-284.
183. Caslini C., Yang Z., El-Osta M., et al. Interaction of MLL amino terminal sequences with menin is required for transformation. Cancer Res 2007, 67:7275-7283.
184. Yokoyama A., Somervaille T.C.P., Smith K.S., et al. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell 2005, 123:207-218.
185. Zhou H., Liu L., Huang J., et al. Structure-based design of high-affinity macrocyclic peptidomimetics to block the menin-mixed lineage leukemia 1 (MLL1) protein-protein interaction. JMed Chem 2013, 56:1113-1123.
186. Daigle S.R., Olhava E.J., Therkelsen C.A., et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 2011, 20:53-65.
187. Chen L., Deshpande A.J., Banka D., et al. Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l. Leukemia 2013, 27:813-822.
188. Daigle S.R., Olhava E.J., Therkelsen C.A., et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood 2013, 122:1017-1025.
189. Yu W., Chory E.J., Wernimont A.K., et al. Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors. Nat Commun 2012, 3:1288.
190. Anglin J.L., Deng L., Yao Y., et al. Synthesis and structure-activity relationship investigation of adenosine-containing inhibitors of histone methyltransferase DOT1L. JMed Chem 2012, 55:8066-8074.
191. Yao Y., Chen P., Diao J., et al. Selective inhibitors of histone methyltransferase DOT1L: design, synthesis, and crystallographic studies. JAm Chem Soc 2011, 133:16746-16749.
192. Deng L., Zhang L., Yao Y., et al. Synthesis, activity and metabolic stability of non-ribose containing inhibitors of histone methyltransferase DOT1L. Medchemcomm 2013, 4:822-826.
193. Glazer R.I., Hartman K.D., Knode M.C., et al. 3-Deazaneplanocin: a new and potent inhibitor of S-adenosylhomocysteine hydrolase and its effects on human promyelocytic leukemia cell line HL-60. Biochem Biophys Res Commun 1986, 135:688-694.
194. Tan J., Yang X., Zhuang L., et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 2007, 21:1050-1063.
195. Zhou J., Bi C., Cheong L.L., et al. The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML. Blood 2011, 118:2830-2839.
196. Fiskus W., Wang Y., Sreekumar A., et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 2009, 114:2733-2743.
197. Ueda K., Yoshimi A., Kagoya Y., et al. Inhibition of histone methyltransferase EZH2 depletes leukemia stem cell of mixed lineage leukemia fusion leukemia through upregulation of p16. Cancer Sci 2014, 105:512-519.
198. Knutson S.K., Wigle T.J., Warholic N.M., et al. Aselective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol 2012, 8:890-896.
199. McCabe M.T., Ott H.M., Ganji G., et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012, 492:108-112.
200. Verma S.K., Tian X., LaFrance L.V., et al. Identification of potent, selective, cell-active inhibitors of the histone lysine methyltransferase EZH2. ACS Med Chem Lett 2012, 3:1091-1096.
201. Qi W., Chan H., Teng L., et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci U S A 2012, 109:21360-21365.
202. Knutson S.K., Warholic N.M., Wigle T.J., et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc Natl Acad Sci U S A 2013, 110:7922-7927.
203. Zhang J., Ding L., Holmfeldt L., et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012, 481:157-163.